TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06359782
Drug: C1 Esterase Inhibitor Injection [Cinryze]
Normalized name: C1 esterase inhibitor Injection [Cinryze]
Approvals — FDA: no, EMA: no, PMDA: no
Description: C1 Esterase Inhibitor Injection \[Cinryze\]
Study: NCT06359782
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium Chloride /physiological saline (0.9%) in equal volume dosed intravenous
Study: NCT04858139
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection (20 min)
Study: NCT06400121
Drug: Apimostinel Infusion, Intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single injection of Apimostinel (10mg)
Study: NCT06400121
Drug: Isotonic Solution, Intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single injection of placebo
Study: NCT04643002
Drug: SAR439459
Normalized name: MAB HUMAN (IGG4) ANTI P01137 (TGFB1_HUMAN) OR ANTI P61812 (TFGB2_HUMAN) OR ANTI P10600 (TGFB3_HUMAN)(SAR439459)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Solution for injection; Route of administration: Intravenous
Study: NCT06798025
Drug: Punctal dilation and topical medication
Normalized name: zinc pyrithione Medicated Shampoo [Free and Clear]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients were treated with a combination of punctal dilation and topical medication in the form of preservative-free steroid eye drops based on dexamethasone sodium phosphate (0.1%) and preservative-free artificial tears based on sodium hyaluronate, polyethylene, and propylene Glycol.
Study: NCT05966064
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo randomized at baseline and after 3 months
Study: NCT05063786
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1250 or 1000 mg/m2 (per investigator preference) twice a day (BID) oral, 2 weeks on, 1 week off, every 3 weeks.
Study: NCT06384976
Drug: Standard lymphodepletion regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: CYC/FLU
Study: NCT06401538
Drug: BMB-101
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMB-101 liquid administered orally twice a day for 3 months
Study: NCT05198960
Drug: Direct Oral Anticoagulants
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients randomized to receive DOAC, at the choice of the investigator: Apixaban 2.5 mg both in day or Rivaroxaban 10 mg once daily.
Study: NCT06696768
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT06696768
Drug: Leucovorin Calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT06537999
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Day 1: IV infusion of placebo~* Week 1 to Week 15: placebo administered SC every 2 weeks
Study: NCT05495464
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given by IV (vein)
Study: NCT05599048
Drug: Hyperpolarized 13C-Pyruvate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT05599048
Drug: 13C,15N-Urea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT06547151
Drug: AMOR-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational arm: Tablets containing 250mg elemental calcium from Amorphous Calcium Carbonate (ACC).
Study: NCT06547151
Drug: Crystalline Calcium Carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control arm: Crystalline Calcium Carbonate (CCC) oral tablet contains 500 mg elemental calcium.
Study: NCT06597201
Drug: glucose peritoneal dialysis solution
Normalized name: glucose Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects received conventional treatment with glucose peritoneal dialysis solution (lactate), which must include 1.5% glucose peritoneal dialysate (lactate) (2L) once.
Study: NCT06737536
Drug: NNC0662-0419
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive NNC0662-0419 subcutaneous (s.c.) once weekly.
Study: NCT06713447
Drug: NTI164
Approvals — FDA: no, EMA: no, PMDA: no
Description: This intervention uses Full-Spectrum Medicinal Cannabis Plant Extract with a low THC concentration of 0.08% (NTI164) specifically formulated to target inflammation in various neurological conditions. The dose of 20mg/kg has been selected based off existing clinical trial evidence for NTI164, and is similar to the dose of other cannabis-based drugs used in neurology. The safety of NTI164 has been rigorously tested in several ongoing paediatric clinical trials through blood tests and clinician-rated surveys.
Study: NCT05338632
Drug: Narcan 40 MG/ML Nasal Spray
Normalized name: Narcan 40 MG/ML Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: naloxone 4mg/0.1 mL intranasal spray, up to 4 doses intranasally, followed by 1ml 0.4 mg/ml naloxone hydrochloride intravenously
Study: NCT06758882
Drug: Androgen receptor (AR) inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: administration of androgen deprivation therapy
Study: NCT06760182
Drug: TQH2722 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQH2722 injection is a humanized monoclonal antibody targeting interleukin-4 receptor alpha (IL-4Rα).
Study: NCT06760182
Drug: TQH2722 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo without drug substance.
Study: NCT05757167
Drug: Artemether-Lumefantrine 20 Mg-120 Mg Oral Tablet
Normalized name: artemether-lumefantrine 20 mg-120 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablets: 6 doses of 80/480 mg over 3 days
Study: NCT06747520
Drug: ET-26HCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dose is 0.8 mg/kg, single dose, Infusion time was 60s ± 5s.
Study: NCT06746701
Drug: Nucleotide Analogues
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starting from the first day of enrollment, take NA orally once a day.
Study: NCT04656418
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buffer without active ingredient
Study: NCT06770114
Drug: Cetylpyridinium Chloride and Zinc Lactate Mouthwash
Normalized name: cetylpyridinium chloride / zinc chloride Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 .075 % cetylpyridinium chloride and 0 .28 % zinc lactate
Study: NCT06770114
Drug: PhosFlur Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 .044 % sodium fluoride
Study: NCT05681442
Drug: continuous pivotal βL-AB
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: continuous pivotal βL-AB
Study: NCT05681442
Drug: intermittent pivotal βL-AB
Normalized name: Crotalidae immune F(ab')2 Injection [Anavip]
Approvals — FDA: no, EMA: no, PMDA: no
Description: intermittent pivotal βL-AB (IID = control group)
Study: NCT05681442
Drug: AG infusion for 5 days
Approvals — FDA: no, EMA: no, PMDA: no
Description: AG infusion for 5 days (ACT Group)
Study: NCT06762600
Drug: HRS-4729 injection placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRS-4729 injection placebo
Study: NCT06762600
Drug: HRS9531 injection placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRS9531 injection placebo
Study: NCT06762600
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen
Study: NCT06752590
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets once daily
Study: NCT06767085
Drug: Saline spray
Normalized name: Saline Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: saline spray on the cervix and cervical canal 5-7 minutes prior to the procedure
Study: NCT05508737
Drug: Pembrolizumab (Keytruda®), Trifluridine/Tipiracil (Lonsurf®)
Approvals — FDA: no, EMA: no, PMDA: no
Description: arms : Pembrolizumab 400 mg every 6 weeks (Q6W), trifluridine/tipiracil at 35 or 30 mg/m2 twice daily (BID) for 5 days a week (D1-5, D8-12) with 2 days rest for 2 weeks, followed by a 14-day rest, repeated every 4 weeks (Q4W)
Study: NCT05333471
Drug: MTP 101-LF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each unit of MTP-101-LF contains approximately 35 mL of fecal transplant product. Participants will receive approximately 32 mL via colonoscopy.
Study: NCT06740188
Drug: 5-hydroxytryptamine balanced antidepressants trazodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: The intervention group was given only 5-hydroxytryptamine balanced antidepressants trazodone
Study: NCT06191315
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Injection solution Route of administration: Subcutaneous
Study: NCT06372145
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:Tablet-Route of administration:oral
Study: NCT05973851
Drug: Second-line Antidepressants
Normalized name: Gallus gallus gizzard lining preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: See arm description
Study: NCT05557045
Drug: JZP815
Approvals — FDA: no, EMA: no, PMDA: no
Description: JZP815 will be administered as oral capsules to participants BID approximately 12 hours apart, in the morning and in the evening. QD dosing may also be investigated, if supported by PK data.
Study: NCT04584983
Drug: usual prescribed intralipid (UL) regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralipid will be started at 1 g/kg/day and routinely advanced by 1 g/kg/day each day to a max of 3 g/kg/day as per usual clinical practice
Study: NCT04584983
Drug: restricted prescribed intralipid (RL) regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralipid will be started at 0.5 g/kg/day and routinely advanced by 0.5 g/kg/day each day to a max of 1.5 g/kg/day (half rate of usual clinical practice).
Study: NCT06782477
Drug: STAR-0310
Normalized name: STAR FRUIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: STAR-0310 will be administered as a subcutaneous bolus injection.
Study: NCT06761417
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 1000 mg/m\^2, d1-14, bid; Each 21-day cycle was used for a total of 4-6 cycles.
Study: NCT06420765
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suspension for oral administration.
Study: NCT06754085
Drug: Florastamin[18F] Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subjects will be intravenously injected with a single dose of 7±1 mCi (259±37 MBq) of Florastamin\[18F\] Injection and undergo PET/CT scan at 60-110 min after the injection.
Study: NCT06767527
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo via IV infusion
Study: NCT06758544
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 21 days/cycle, administered up to 6 cycles
Study: NCT06767683
Drug: ALKS 2680, 4mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet containing 4 mg of ALKS 2680 for once daily administration
Study: NCT06767683
Drug: ALKS 2680, 6mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet containing 6 mg of ALKS 2680 for once daily administration
Study: NCT06767683
Drug: ALKS 2680, 8mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet containing 8 mg of ALKS 2680 for once daily administration
Study: NCT05616260
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar capsule manufactured to match encapsulated Acetazolamide
Study: NCT06778850
Drug: MDR-001
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of small molecule MDR-001 tablets
Study: NCT06778850
Drug: palcebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally placebo
Study: NCT06791161
Drug: Endocrine drug +CDK4/6 inhibitor or PRAP inhibitor or Endocrine drug +CDK4/6 inhibitor+PARP inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: BRCA1/2 mutated hormone receptor-positive HER2-negative early high-risk breast cancer is treated with 3 3 treatment options after surgery：Endocrine drug +CDK4/6 inhibitor or PRAP inhibitor or Endocrine drug +CDK4/6 inhibitor+PARP inhibitor
Study: NCT06388083
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets
Study: NCT06609928
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT06775275
Drug: Adebellizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: adebrelimab
Study: NCT06774846
Drug: Acetylsalicylic acid/Aspirin (100 mg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive 100 mg acetylsalicylic acid (or Aspirin) orally (tablet) once a day (or intravenously if oral administration is not possible in the acute phase of pneumonia), introduced within 84 hours of pneumonia diagnosis, for 90 days.
Study: NCT06774846
Drug: Placebo acetylsalicylic acid (100 mg) / 0.9% sodium chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients in the placebo group will receive 100 mg placebo acetylsalicylic acid orally (tablet) once a day (or intravenously if oral administration is not possible in the acute phase of pneumonia), introduced within 84 hours of pneumonia diagnosis, for 90 days.
Study: NCT06765733
Drug: Aleeto
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aleeto is a nerve repair protein developed by Darwin Start (Beijing) Biopharmaceutical Co., Ltd. It is a group of specific microenvironmental protein polymers secreted under the emergency conditions of stem cells. It has the advantages of selective assembly, targeted delivery, efficient repair of damaged tissues, high safety, chemical stability, easy storage, etc., and has a powerful neural repair function. According to the groups, patients would be treated with Aleeto via intrathecal injection or intravenous injection.
Study: NCT06765954
Drug: M-CENK (Activated NK Cells)
Normalized name: m-phenylenediamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered intravenously (IV) before and after radiation therapy, also with variations in the timing and dosing across different cohorts.
Study: NCT06799546
Drug: HSK39297 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg QD for 24 weeks
Study: NCT06782373
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplied in hard capsules.
Study: NCT05993884
Drug: iEPCs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given: IV
Study: NCT06759181
Drug: anti-BCMA/FcRL5 CAR T
Approvals — FDA: no, EMA: no, PMDA: no
Description: anti-BCMA/FcRL5 autologous CAR T cells will be infused at a dose ranging from 1 - 2 x 10\^6/kg CAR+ T cells after receiving lymphodepleting chemotherapy.~Other Name:
Study: NCT06747923
Drug: SB17170
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taking SB17170 orally once a day
Study: NCT06747923
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taking Placebo orally once a day
Study: NCT06748014
Drug: MPFF
Normalized name: Micronized Purified Flavonoid Fraction
Approvals — FDA: no, EMA: no, PMDA: no
Description: MPFF 3000 mg 7 day then 1000 mg 2 months
Study: NCT06741644
Drug: CS2009
Approvals — FDA: no, EMA: no, PMDA: no
Description: CS2009 will be administered via intravenous (IV) infusion on Day 1 of repeated 21-day cycles (Q3W).
Study: NCT06750991
Drug: CDR-CHOP
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rituximab 375 mg/m2 D1 Cyclophosphamide 750 mg/m2 D2 Doxorubicin 50 mg/m2 D2 Vincristine 1.4 mg/m2 D2 Prednisone 69 mg.m2 D2-6 Chidamide 20 mg/d D1,4,8,11 Decitabine 10 mg/m2 D-5 - -1
Study: NCT06750744
Drug: Tigecycline (Tygacil)
Normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: selective antibiogram
Study: NCT05418101
Drug: VIS171
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive VIS171 via SC route of administration.
Study: NCT05418101
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive Placebo via SC route of administration
Study: NCT06454669
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo will be prepared and administered in the same manner as the active medication. Titration will occur in a masked fashion such that individuals assigned to placebo undergo a similar perceived titration process.
Study: NCT06763172
Drug: Caffeine (200 mg)
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine (200mg) will be administered per os 20 minutes prior to the PET/fMRI data acquisition.
Study: NCT06763172
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactose tablet will be administered per os 20 minutes prior to the PET/fMRI data acquisition.
Study: NCT06585787
Drug: KarXT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT06585787
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT04566887
Drug: R-CHOP chemotherapy
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-CHOP chemotherapy
Study: NCT06753786
Drug: Venous thromboembolism prophylaxis with unfractionated heparin or low molecular weight heparin starting within the first 2 days but not earlier than 12 hours after a hospital admission.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic dosage and administration of unfractionated heparin or low molecular weight heparin according to their official prescribing information.
Study: NCT06753786
Drug: Venous thromboembolism prophylaxis with unfractionated heparin or low molecular weight heparin starting on the 3rd day after a hospital admission.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic dosage and administration of unfractionated heparin or low molecular weight heparin according to their official prescribing information.
Study: NCT06753526
Drug: L-Arginine, 500 Mg Oral Capsule
Normalized name: L-Arginine, 500 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: group 2by twice dose
Study: NCT06777316
Drug: CGT4859
Approvals — FDA: no, EMA: no, PMDA: no
Description: CGT4859 is a selective FGFR2/3 inhibitor
Study: NCT06532396
Drug: QRL-101
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple-ascending doses of QRL-101 will be orally administered. The dose levels may change subject to available nonclinical, clinical, safety, and PK data.
Study: NCT06532396
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple-ascending doses of comparator placebo will be administered orally to healthy participants.
Study: NCT05605496
Drug: anti-PD-1/PD-L1
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion, Q3W or Q6W anti-PD1/PDL1 are standard treatments and are prepared and administred as per respective SmPC and institutional practice.
Study: NCT05732831
Drug: TNG462
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNG462, a selective PRMT5 inhibitor, will be administered orally
Study: NCT06769256
Drug: rhTNK-tPA, 4-8 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary influsion of rhTNK-tPA (4 mg). After 10 minutes of administration, 4 mg may be given again if the thrombus burden is not significantly reduced.
Study: NCT06747585
Drug: ALE.P02
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALE.P02, will be administered by IV infusion according to the assigned arms.
Study: NCT06746064
Drug: Placebo (Part 1 - SAD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single doses of placebo matching CHF10073 for each cohort
Study: NCT06774144
Drug: Standard of care antifungal prophylaxis
Approvals — FDA: no, EMA: no, PMDA: no
Description: UPMC uses a tiered approach to antifungal prophylaxis, based on risk factors for IFI. Fluconazole is used for recipients with risk factors for yeast infections: choledochojejunostomy, prolonged transplant time, receipt of \>40 units of blood products within 24 hours of transplant, and Candida colonization or infection within 3 months prior to transplant. Voriconazole is used for recipients with risk factors for mould infections: re-transplantation, renal failure requiring renal replacement therapy, fulminant hepatic failure as indication for transplant, intra-abdominal/thoracic re-exploration within the first month after transplant. No prophylaxis is given if there are no risk factors for yeast or mould infections.
Study: NCT06771544
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT06775483
Drug: JSKN016
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered intravenously according to protocol.
Study: NCT06750783
Drug: Xuezhikang
Approvals — FDA: no, EMA: no, PMDA: no
Description: The Xuezhikang group takes Xuezhikang at a dose of 600 milligrams twice a day, orally after meals;
Study: NCT06775405
Drug: AK0529
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active Substance: AK0529, Pharmaceutical Form: Enteric pellets, Route of Administration: Oral
Study: NCT06775405
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active Substance: Placebo, Pharmaceutical Form: Enteric pellets, Route of Administration: Oral
Study: NCT06776445
Drug: minocycline combined with hydroxychloroquine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with rosacea were collected and randomly divided into three groups for treatment, one group was treated with minocycline combined with hydroxychloroquine, one group was treated with gabapentin 300mg Bid, and the other group was treated with gabapentin 300mg tid. Before treatment, 4 weeks after treatment, and 8 weeks after treatment, the patient's condition score was statistically analyzed, and the efficacy and difference of each group were observed
Study: NCT06776198
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group IE/F: After progression, try LRRC15 ADC + PD-1 inhibitors; Group IE: After progression, try simple anti-PD-1 inhibitors; Group F: After progression, try LRRC15 ADC; Group D: After progression, try B7-H3 ADC or other irrinotecan analogue
Study: NCT06549595
Drug: AZD0486
Approvals — FDA: no, EMA: no, PMDA: no
Description: a fully human bispecific monoclonal IgG4 antibody
Study: NCT06549595
Drug: R-CHOP
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone
Study: NCT06549595
Drug: R-CVP
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab, Cyclophosphamide, Vincristine and Prednisone
Study: NCT04886258
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05225324
Drug: Equfina 50 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Equfina 50 mg tablets.
Study: NCT06756334
Drug: [18F]AlF-PSMA-N5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject receive a single intravenous injection of \[18F\]AlF-PSMA-N5, and undergo PET/CT imaging within the specificed time.